Background: Drug delivery into the brain has been a challenge for the past 100 years because of the blood brain barrier. The existing non-invasive techniques cannot provide controlled and continuous drug delivery into the brain and the invasive techniques make the brain prone to infection from external agents. Hence a new technique which can provide controlled and continuous drug delivery without the need for any surgical intervention in the brain holds immense potential.
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BACKGROUND:
It is more than 100 years since the blood brain barrier was discovered [1] . The blood brain barrier protects the brain from external agents. But this natural protection also prevents 98% of the small drugs and 100% of the large drugs available today from entering the brain in concentrations that can produce the required therapeutic effects [2] .
In Parkinson's disease, focus is currently on techniques to effect continuous tonic firing of diseased dopamine neurons as in normal physiologic conditions. But dopamine does not cross the blood brain barrier normally.
In Alzheimer's disease, focus is currently on immunotherapy.
But, the entry of the peripherally administered antibodies into the brain has been limited to around 0.1% to 0.2% by the blood brain barrier.
In tumors involving the brainstem, the prognosis has been poor because drug delivery is restricted by the blood brain barrier.
In the eye, retinal drug delivery is a challenge till date because of the blood retinal barrier.
This novel device and technique address the issue of delivering drugs into the brain. 4 The device is implanted in the oral or maxillofacial region and the drugs are delivered directly into the connective tissue of the respiratory mucosa of the maxillary sinus, from where the drugs get transferred into the brain including the optic nerve through the neural, lymphatic and vascular pathways.
This technique is advantageous because it avoids the iatrogenic brain damage caused by the existing invasive techniques like convection enhanced drug delivery. It also provides continuous and controlled drug delivery which is not feasible with the existing non-invasive techniques like nasal drug delivery, receptor mediated transport, ultrasound mediated opening of blood brain barrier etc.
This technique provides access to the optic nerve and vessels and therefore can deliver drugs into the retina and the vitreous.
MATERIALS AND METHODS:
The in vivo proof of concept study was done using a rabbit model in an OECD GLP certified pre-clinical research lab with a CPCSEA approved animal lab facility and accredited by the In the control model, anesthesia was given and the bone window was prepared. But, no dopamine was infused. It was used for studying the normal dopamine concentration in the brain tissue.
Cardiac perfusion was done using saline to clear the brain of any residual blood under deep surgical anesthesia. Before and during the perfusion, the animal was monitored visually for withdrawal reflex. The perfusion was carried out in necropsy hood using a peristaltic pump to deliver the warm physiological saline at controlled speed. The left ventricle was identified and a small cut was given at the apex to insert the perfusion cannula into the ventricle till it reached the aorta.
The inserted cannula was then clamped in place and normal saline was infused. The right atrium was then opened and the animal was perfused with normal saline for 15 to 20 minutes to remove the blood completely.
Once, most of the visceral organs turned pale in color, perfusion was stopped. The cleared brain was removed carefully and stored in dry ice. Duramater adhering to the cranial cavity and the nasal mucosa were removed and stored in dry ice. The tissue samples were homogenized with buffer, centrifuged and subjected to HPLC. The plasma samples were also subjected to HPLC.
Ex-Vivo animal model:
The blood brain barrier has been found to be structurally maintained after death for a few hours at least in relation to large molecules [3] . Therefore, it was decided to use a goat head which was procured immediately after decapitation from an abattoir to assess the feasibility of delivery of large antibodies across the blood brain barrier using the new with part of the optic nerve and stored in dry ice. Vitreous was aspirated from the eye using a 5ml syringe through a transscleral approach and stored in dry ice. The tissue samples were homogenized with buffer, centrifuged and subjected to HPLC. The Cortex showed an increase of 256.5%. The Optic nerve showed an increase of 128.8% and the Vitreous showed an increase of 289.67%. A t-test performed using SPSS software version 20.0 (SPSS Inc., Chicago, IL) found the changes to be statistically significant (p=0.047)
RESULTS:
IN VIVO RABBIT MODEL-DOPAMINE
DISCUSSION:
A proof of concept study was conducted to test the efficacy of a new technique and device for delivering drugs into the brain including the optic nerve. An In-vivo study using a rabbit model and an Ex-vivo study using a freshly decapitated goat head was done. Drugs which normally do not cross the blood brain barrier were selected for the study. Dopamine, a small molecule and Anti-gfap, a large antibody were tested using this device to assess whether drugs of different sizes can be delivered using this technique.
In the in vivo study, the connective tissue underlying the respiratory mucosa of the maxillary sinus was surgically accessed by creating a window on the overlying bone [4] . The prototype of the device was strategically placed with its delivery tip located beneath the respiratory mucosa. A pump was used to deliver dopamine in a controlled and continuous manner.
Trigeminal nerve supplies the nasal respiratory mucosa and the maxillary sinus mucosa and relays at the Pons [5] .
Cerebrospinal fluid drains through nasal lymphatics which are free of valves [6] . The veins from parts of the maxillary sinus and the nasal region drain into the pterygoid venous plexus and reach the cavernous sinus [7] ; [8] . Studies have shown retrograde dopamine transfer in the cavernous sinus because of counter current mechanism in perfused ex vivo rabbit models [9] . Hence the drug delivered directly into the connective tissue of the respiratory mucosa, may be transported from the nasal and maxillary sinus region through the neural [5] ; lymphatic [6] ; and the paravascular [10] routes into the brain.
Dopamine concentration in Midbrain, which is the target for
Parkinson, showed an increase of 27% when compared with the control. The Cortex showed an increase of 72.637% when compared with control. These values show that these therapeutic sites can be accessed and dopamine can be delivered across the blood brain barrier without any direct surgical intervention in the brain. Moreover sufficient concentration of the drug can be maintained at the site for producing the therapeutic effect. The significant increase shows that very low concentration of drugs may be used to produce therapeutic effects in the brain. By using controlled drug delivery or slow release formulations it will be possible to 13 provide continuous drug delivery into the brain for a longer period of time. This technique can therefore produce continuous tonic stimulation of the dopamine receptors.
Duramater showed an increase of 36.52%.The infused dopamine may be delivered by retrograde paravascular transport through branches of the maxillary artery and through the pterygoid venous plexus into the duramater. Moreover Duramater is also supplied by afferent branches from the trigeminal ganglion and the sphenopalatine ganglion in the anterior and middle cranial fossa. Therefore neural pathway also may play a role in the delivery of the infused dopamine.
Lymphatic pathway also may be involved.
Cerebellum showed an increase of 21.75%. The Medulla and Pons showed an increase of 48.5% and 51.8% respectively. Similarly, the Olfactory Bulb and Tract showed a decrease of -6.1238% when compared with the control. The increase in dopamine in the primary olfactory relay area in the cortex or decrease in the secondary relay area in the thalamus may have caused a decrease in the Olfactory Bulb and Tract dopamine by a feedback mechanism. This finding may be significant in analyzing the cause and treatment options for olfactory dysfunction in Parkinson's [13] .
The Optic Nerve showed a decrease of -15.746% when compared with the control. The retina and the optic nerve have dopaminergic innervation. The optic pathway from the retina relays in the lateral geniculate ganglion in the Thalamus which further relays in the visual cortex. The retinal efferent also relays in the pulvinar of the thalamus, superior colliculus, and midbrain tectum. Therefore excess dopamine in these sites can decrease dopamine in optic nerve by a feedback mechanism. In this study, the increase in dopamine in the midbrain, the cortical and the sub-cortical sites along with the decrease in dopamine in the diencephalon may have caused a decrease in the optic nerve dopamine by a feedback mechanism. Visual dysfunction is also seen in Parkinson's [14] ; [15] . Hence this finding may be significant.
In spite of significant changes at multiple sites, the dopamine variation in the experimental model was not statistically significant when compared with the control. This further emphasizes the innate tight control by the feedback mechanism of the brain. The feedback mechanism may maintain the total brain dopamine within a range.
Similarly, the blood values showed a decrease of -0.16% in dopamine levels at 10 minutes. The dopamine values dipped further to -0.70% at 20 minutes. It correlated with the time the drug was being infused (Fig: 4) .Once the dopamine infusion was stopped at 20 minutes, the blood values again peaked at 30 minutes. The dopamine value at 30 minutes was higher by 17 0.069% than that at 0 minutes. This finding is significant because there may be a central control of peripheral dopamine release and peripheral dopamine may be mildly inhibited during the infusion. Moreover this technique does not cause any significant increase of dopamine in the peripheral circulation which may have clinical significance.
It is accepted that the blood brain barrier is maintained at least in relation to large molecules after death. The study by Hossmann and Olson on a cat model found that intravenously injected Evans blue and horse radish peroxidase did not cross the blood brain barrier for up to 3 hours even when acute complete cerebral ischemia was caused by arterial ligation [3] . It has also been noted that the brain is less subject to postmortem redistribution of drugs when compared with other organs [16] .
Therefore an ex-vivo study using a goat head following immediate decapitation was done to assess the efficacy of the new drug delivery device and technique. Anti-gfap antibody was delivered under the connective tissue of the palatine respiratory mucosa of a freshly decapitate goat head using the device.
Recently paravascular transport pathways which are analogous to the glymphatic pathways in the brain have been 18 reported in the retinal vasculature and the optic nerve. It has also been postulated that the paravascular transport pathways may provide drainage from the optic nerve to beneath the internal limiting membrane which forms the boundary between the vitreous and the retina [17] . [18] [19].
It has been shown that fluorescent dextran tracers of 10, 40, 70 and 500kDa sizes, when injected into the CSF at the cisterna magna of mice enter the sub arachnoid space of the orbital optic nerve. While the tracers ranging in size from 10kDa to 40kDa were also seen within the optic nerve, the tracers of 70KDa size had only limited distribution within the optic nerve and the tracers of 500kDa size could not be detected [20] .
Intravitreal drug delivery studies have shown that the negatively charged inner limiting membrane has pores of approximately 10nm and does not limit retinal drug delivery of compounds below 100kDa [21] .
Therefore drugs delivered beneath the internal limiting membrane of the retina through paravascular transport pathways may also reach the vitreous.
The HPLC study result showed that the concentration of the antibody decreased in the following order Vitreous >Cortex > Optic Nerve > Pons > Palatine sinus mucosa > Duramater. In the study model, the antibody concentration in the respiratory mucosa of the palatine sinus increased by 1.3 fold when compared with the control. In the duramater it increased by 1.2 fold and in the pons by 1.8 fold. The cortex showed a 3.5 fold increase. The optic nerve showed a 2.2 fold increase and the vitreous showed a 3.8 fold increase. The increase of antibody in the vitreous is of clinical significance. The drug could have reached the retina by bypassing the blood retinal barrier through the optic nerve and vessels. It may have further entered the vitreous through the inner limiting membrane. The high concentration of the antibody in the optic nerve therefore shows that a perineural drug delivery route to the retina from the brain is a possibility.
CONCLUSION:
The new drug delivery system and technique can be used for continuous and controlled delivery of drugs into the brain Retina and the central nervous system have a number of similarities that include a common origin of development from the neural tube, presence of a blood-retinal barrier and a blood-brain barrier respectively and the occurrence of age related extra cellular deposits comprising βamyloid referred to as drusen in the retina and as senile plaques in the brain [22] .
As it has been shown that the retina and the vitreous can be accessed through the optic nerve, this device and technique can be used for treating diseases of the eye too.
The goat head may be useful as an ex-vivo model for testing delivery of large molecules into the brain along with in vitro models.
As this study is a proof of concept study, further studies with larger sample sizes will be required in the future. Figure 1 shows the experimental model where dopamine is given in a controlled and continuous manner using an external drug infusion pump.
FIGURE LEGENDS
27 Figure 2 shows the intra-oral technique.
28 Figure 3 compares the concentration of dopamine in the brain, duramater and the maxillary sinus respiratory mucosa between the experimental model and the control.
29 Figure 4 compares the concentration of dopamine in the blood in the experimental model during the dopamine infusion period.
30 Figure 5 compares the concentration of anti-gfap antibody in the brain, duramater, vitreous and palatine sinus respiratory mucosa between the experimental model and the control.
